
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
The author discusses why two of the industry's common practices for preventing microorganism contamination in USP hot-ware and purified-water systems may have no scientific basis.
almost 23 years ago
Big Pharma Works on Productivityalmost 23 years ago
Electronic Information Systemsalmost 23 years ago
CMO-grown Innovation and Technologyalmost 23 years ago
Segregation of Powders during Gravity Flow Through Vertical Pipes





